Coronary Microvascular Dysfunction Clinical Trial
Official title:
Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults
GLP-1 is an agent for treatment of type 2 diabetes and may have protective effects on the
cardiovascular system. The mechanism is complex and there seems to be a dual function with
intact GLP-1 (7-36), acting through the GLP-1 receptor, and the GLP-1 (9-36) metabolite
acting independently of the GLP-1 receptor.
Coronary flow reserve (CFR) is the ratio of flow through the coronary arteries during stress
to during rest and it reflects coronary microcirculation. Impaired CFR is a strong predictor
of poor prognosis of cardiovascular disease.
The aim of the study is to investigate the acute effects of GLP-1 on coronary
microcirculation and endothelial function in adults with obesity.
Several studies have shown beneficial effects of glucagon-like-peptide-1 (GLP-1) on the
cardiovascular system. Native GLP-1 is secreted from L-cells in the intestine as GLP-1(7-36)
1 but is rapidly metabolised by the ubiquitous enzyme dipeptidyl-peptidase-4 (DPP4) to the
metabolite GLP-1(9-36). However, the physiological effect of GLP-1 on the cardiovascular
system is complex and there seems to be a dual function with intact GLP-1 (7-36), acting
through the GLP-1 receptor, and the GLP-1 (9-36) metabolite acting independently of the GLP-1
receptor.
The aim of the study is to investigate the acute effects of intact GLP-1 and GLP-1 metabolite
on coronary microcirculation and endothelial function in adults.
Method 20 adults with obesity are recruited to a double-blind randomized cross-over study.
The first 10 included adults will receive 2½ hours infusion of intact GLP-1 (7-36) together
with a DPP-IV inhibitor and 2½ hours infusion of saline, on two separate occasions. The
infusions will be given in randomized order with a minimum of 24 hours washout period.
The next 10 included adults will receive 2½ hours infusion of GLP-1 (9-36) metabolite and 2½
hours infusion of saline. These will also be given in randomized order with a minimum of 24
hours washout period. Endothelial function and CFR will be measured before and after one,
respectively two, hours of infusion.
The effect of GLP-1 infusions on microvascular function is evaluated by coronary flow reserve
(CFR), the ratio between echocardiographic measured coronary flow velocity in LAD during
adenosine induced myocardial hyperaemia and rest. The effect on endothelial function is
assessed by flow mediated dilation (FMD).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06306066 -
Coronary Thermo-dilution Derived Flow-indices in Chronic Coronary Syndrome
|
||
| Recruiting |
NCT05288361 -
The DISCOVER INOCA Prospective Multi-center Registry
|
||
| Terminated |
NCT04614467 -
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
|
Phase 2 | |
| Recruiting |
NCT06089031 -
Belgian Registry on Coronary Function Testing
|
||
| Enrolling by invitation |
NCT06083155 -
The NetherLands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT)
|
||
| Completed |
NCT05009667 -
A Prospective, Multi-center Clinical Trial for Evaluating the Effectiveness and Safety of Online Coronary Angiography-Derived Index of Microcirculatory Resistance (caIMR)
|
||
| Active, not recruiting |
NCT05197361 -
Microvascular Coronary Resistance and Absolute Coronary FLOW in Patients With Percutaneous Intervention of a Chronic Total Occlusion
|
||
| Recruiting |
NCT05825339 -
Absolute Flow for Ischemia With No Obstructive Coronary Arteries
|
||
| Recruiting |
NCT05294887 -
Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease
|
Phase 4 | |
| Not yet recruiting |
NCT05790876 -
Super Saturated Oxygen (SSO2) Therapy in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Action on Coronary Microcirculation Dysfunction
|
N/A | |
| Completed |
NCT04959357 -
The Evaluation of Left Ventricular Systolic Function in Different Types of Ischemic Heart Disease
|
||
| Completed |
NCT04523168 -
Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction
|
N/A | |
| Recruiting |
NCT05711719 -
Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
|
Phase 2 | |
| Recruiting |
NCT06294730 -
COronary Microcirculation and Troponin Elevation in Septic Shock
|
||
| Recruiting |
NCT05841485 -
COVID-19 Microvascular Evaluation Trial
|
||
| Recruiting |
NCT03876223 -
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
|
||
| Completed |
NCT05471739 -
Simultaneous Assessment of Coronary Microvascular Dysfunction and Ischemia With Non-obstructed Coronary Arteries With Intracoronary Electrocardiogram and Intracoronary Doppler
|
||
| Completed |
NCT01014949 -
Microcirculation Assessment in Diabetes and Metabolic Syndrome
|
N/A | |
| Active, not recruiting |
NCT06008041 -
Multimodal Epicardial and Endocardial COronary PHYsiological Evaluation in Pathological Situations (PHYCO)
|
||
| Recruiting |
NCT05984537 -
A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.
|
Phase 4 |